|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2122232425262728293031...6768» |
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., bendamustine / Generic mfg.
Enrollment closed, Trial primary completion date: Bendamustine, Lenalidomide (Revlimid (clinicaltrials.gov) - Jun 12, 2015
P2, N=50, Active, not recruiting, Sponsor: Cantonal Hospital of St. Gallen
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jan 2016
- Trial primary completion date: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jan 2016 Trial primary completion date: Dec 2014 --> Jan 2018
- bortezomib / Generic mfg.
Preclinical, Trial primary completion date: Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Dec 2014 --> Jan 2018 Trial primary completion date: Oct 2015 --> Oct 2016
- bortezomib / Generic mfg.
Enrollment closed, Trial primary completion date: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - Jun 11, 2015
P2, N=10, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Jun 11, 2015
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Feb 2016 --> May 2016
- simvastatin / Generic mfg.
Trial primary completion date: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins (clinicaltrials.gov) - Jun 11, 2015
P0, N=30, Recruiting, Sponsor: University of New Mexico
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Jun 2013 --> Jun 2019
- || dexamethasone / Generic mfg., melphalan / Generic mfg., pomalidomide / Generic mfg.
Clinical: IFM2010-02: Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) (clinicaltrials.gov) - Jun 11, 2015
P2, N=55, Active, not recruiting, Sponsor: University Hospital, Lille
Trial primary completion date: Jun 2013 --> Jun 2019 Trial primary completion date: Dec 2014 --> Dec 2015
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Apr 2015 --> Dec 2015
- || Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Active, not recruiting, Sponsor: Craig Hofmeister
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- Trial withdrawal: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Jun 2015 --> Dec 2015 Terminated --> Withdrawn
- Enrollment change, Trial termination, Trial primary completion date: Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=9, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=52 --> 9 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Dec 2014; Drugs unavailable. Study did not progress to Phase 2.
- luminespib (AUY922) / Ligand
Enrollment change, Trial termination: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Jun 11, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Study did not progress to Phase 2. N=25 --> 7 | Active, not recruiting --> Terminated; patient safety
- Trial completion, Post-transplantation: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 11, 2015
P0, N=21, Completed, Sponsor: Washington University School of Medicine
N=25 --> 7 | Active, not recruiting --> Terminated; patient safety Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2015
P2, N=29, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2015
- ||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, Trial primary completion date: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Jun 10, 2015
P3, N=51, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2015
- | bortezomib / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial, Combination therapy: REMM: Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance (clinicaltrials.gov) - Jun 9, 2015
P2, N=73, Completed, Sponsor: University Medical Centre Groningen
- celecoxib oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma (clinicaltrials.gov) - Jun 9, 2015
P2, N=23, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2015 Active, not recruiting --> Completed | N=36 --> 23 | Trial primary completion date: Dec 2010 --> Jun 2008
- Mozobil (plerixafor) / Sanofi
Enrollment closed, Trial primary completion date, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - Jun 6, 2015
P4, N=250, Active, not recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed | N=36 --> 23 | Trial primary completion date: Dec 2010 --> Jun 2008 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Jul 2015
- Enrollment open: Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry (clinicaltrials.gov) - Jun 4, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Valencia
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- ||| Farydak (panobinostat) / Secura Bio
Enrollment change, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Jun 4, 2015
P1/2, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=38 --> 52
- ||| azintuxizumab vedotin (ABBV-838) / AbbVie
Clinical: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2015
P1, N=100, Recruiting, Sponsor: AbbVie
- ||| Enrollment open: Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=70, Recruiting, Sponsor: Mayo Clinic
N=38 --> 52 Not yet recruiting --> Recruiting
- dasatinib / Generic mfg.
Enrollment change, Surgery, Metastases: S0711: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 3, 2015
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=42 --> 80
- | Xyntha (moroctocog alfa) / Pfizer
New P1 trial: Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A (clinicaltrials.gov) - Jun 3, 2015
P1, N=12, Not yet recruiting, Sponsor: Pfizer
- ||||| Abstilla (lonoctocog alfa) / CSL Behring
Enrollment closed: Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A (clinicaltrials.gov) - Jun 1, 2015
P3, N=75, Active, not recruiting, Sponsor: CSL Behring
N=42 --> 80 Recruiting --> Active, not recruiting
- Enrollment change: Early Whole Blood in Patients Requiring Transfusion After Major Trauma (clinicaltrials.gov) - May 28, 2015
P4, N=107, Completed, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Active, not recruiting N=73 --> 107
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment open, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - May 27, 2015
P=N/A, N=20, Recruiting, Sponsor: CSL Behring
N=73 --> 107 Not yet recruiting --> Recruiting
- Coagadex (coagulation factor X (human)) / Bio Products Laboratory (BPL)
Enrollment open: A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years (clinicaltrials.gov) - May 27, 2015
P3, N=16, Recruiting, Sponsor: Bio Products Laboratory
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Onmel (itraconazole) / Merz Pharma
Enrollment open: ATRA, Celecoxib, and Itraconazole as Maintenance (clinicaltrials.gov) - May 27, 2015
P1, N=25, Recruiting, Sponsor: University of Iowa
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | tabalumab (LY2127399) / Eli Lilly
Trial completion, Trial primary completion date, Combination therapy: A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib (clinicaltrials.gov) - May 26, 2015
P1, N=48, Completed, Sponsor: Applied Molecular Evolution
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> May 2014
- New trial: DMSOconc3: Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. (clinicaltrials.gov) - May 22, 2015
P=N/A, N=150, Recruiting, Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
- New trial: Fungemia in Hematologic Malignancies (clinicaltrials.gov) - May 22, 2015
P=N/A, N=300, Recruiting, Sponsor: Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
- lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma (clinicaltrials.gov) - May 21, 2015
P3, N=42, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> May 2014 Recruiting --> Completed | N=300 --> 42 | Trial primary completion date: Apr 2015 --> Aug 2014
- Empliciti (elotuzumab) / AbbVie, BMS
Enrollment change, Combination therapy: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (clinicaltrials.gov) - May 21, 2015
P1, N=6, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=300 --> 42 | Trial primary completion date: Apr 2015 --> Aug 2014 N=20 --> 6
- | warfarin / Generic mfg.
Trial completion, Enrollment change: OVWAC VII: Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability? (clinicaltrials.gov) - May 21, 2015
P3, N=235, Completed, Sponsor: St. Joseph's Healthcare Hamilton
N=20 --> 6 Active, not recruiting --> Completed | N=400 --> 235
- Trial completion: Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (clinicaltrials.gov) - May 21, 2015
P1, N=110, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=400 --> 235 Active, not recruiting --> Completed
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - May 20, 2015
P1, N=18, Recruiting, Sponsor: Robert Lowsky
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Beqvez (fidanacogene elaparvovec-dzkt) / Pfizer
Enrollment closed, Gene therapy, Viral vector: Hemophilia B Gene Therapy With AAV8 Vector (clinicaltrials.gov) - May 20, 2015
P1/2, N=15, Active, not recruiting, Sponsor: Spark Therapeutics
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: alloCIK: Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (clinicaltrials.gov) - May 19, 2015
P2, N=24, Completed, Sponsor: Singapore General Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | N=20 --> 24
- New trial: Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma (clinicaltrials.gov) - May 19, 2015
P0, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- | plerixafor / Generic mfg.
Trial completion: Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (clinicaltrials.gov) - May 16, 2015
P2, N=40, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | N=20 --> 24 Active, not recruiting --> Completed
- ||| Trial completion: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 14, 2015
P1, N=52, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- lenalidomide / Generic mfg.
Trial completion, Trial primary completion date: Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma (clinicaltrials.gov) - May 13, 2015
P1/2, N=24, Completed, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2012 --> Mar 2013
- | marzeptacog alfa (CB 813d) / GC Biopharma
Trial completion: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - May 13, 2015
P1, N=24, Completed, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Nov 2012 --> Mar 2013 Active, not recruiting --> Completed
- ||| Enrollment closed: Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (clinicaltrials.gov) - May 12, 2015
P1/2, N=52, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Elitek (rasburicase) / Sanofi
Trial completion: Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - May 12, 2015
P=N/A, N=25, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - May 8, 2015
P3, N=75, Recruiting, Sponsor: Grifols Biologicals Inc.
Recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2017
- || Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial initiation date, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - May 8, 2015
P=N/A, N=2000, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Mar 2014 --> Mar 2017 Initiation date: Mar 2015 --> Jun 2015
- | Zydelig (idelalisib) / Gilead
New P2 trial: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstr (clinicaltrials.gov) - May 8, 2015
P2, N=30, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- Enrollment change, Trial primary completion date: Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers (clinicaltrials.gov) - May 7, 2015
P=N/A, N=24, Recruiting, Sponsor: Case Comprehensive Cancer Center
Initiation date: Mar 2015 --> Jun 2015 N=74 --> 24 | Trial primary completion date: Apr 2015 --> Oct 2015